FibroScan评估酒精性肝病肝纤维化程度的诊断价值

肝脏 ›› 2016, Vol. 21 ›› Issue (9): 719-721.

FibroScan评估酒精性肝病肝纤维化程度的诊断价值

徐微

214000 江苏无锡市第五人民医院肝病科

收稿日期:2016-04-15 出版日期:2016-09-30 发布日期:2020-06-19

The clinical value of FibroScan for evaluating the hepatic fibrosis stage in patients with alcoholic liver disease

XU Wei

Department of Liver Disease, the Fifth People' Hospital of Wuxi, Jiangsu 214000, China

Received:2016-04-15 Online:2016-09-30 Published:2020-06-19

摘要/Abstract

摘要： 目的探讨瞬时弹性成像技术(FibroScan)在评估酒精性肝病肝纤维化程度中的应用价值。方法对60例酒精性肝病患者采用FibroScan测量肝脏硬度,获得FibroScan弹性值(FS值),同时对患者进行肝活组织检查,以病理结果为金标准,分析FS值与酒精性肝纤维化分期的相关性。用受试者工作特征(receiver operating charateristic, ROC)曲线评估FibroScan对酒精性肝病的诊断价值。结果酒精性肝病患者肝纤维化分期S0~S4的FS值分别为S0: (5.31±1.06)kPa、S1: (7.91±2.81) kPa、S2: (9.81±3.39) kPa、S3: (14.66±4.31) kPa、S4: (19.81±6.02) kPa。组间差异有统计学意义(P<0.05)。进一步分析显示FS值与肝纤维化分期呈正相关性(r=0.706,P<0.05)。肝纤维化程度≥S1、≥S2、≥S3和S4的ROC曲线下面积分别为0.833、0.871、0.906和0.919。结论 Fibroscan作为一种无创技术,能够较准确地定量评估酒精性肝病肝纤维化程度。

关键词: 酒精性肝病, 瞬时弹性成像技术, 肝纤维化

Abstract: Objective To investigate the clinical value of FibroScan for evaluating the hepatic fibrosis stage in patients with alcoholic liver disease. Methods In the study, 60 patients with alcoholic liver disease admitted in our hospital from June 2013 to June 2015 were enrolled. The liver stiffness was measured by FibroScan and quantified with FibroScan value, and liver biopsy was also conducted as the gold standard. The correlation between FibroScan value and the stage of hepatic fibrosis was analyzed by receiver operating characteristic (ROC) curve. Results The value of liver stiffness measured by FibroScan from stage 0 to stage 4 were 5.31±1.06, 7.91±2.81, 9.81±3.39, 14.66±4.31 and (19.81±6.02) kPa, respectively. The FibroScan value has a positive correlation with hepatic fibrosis stage in patients with alcoholic liver disease (r=0.706, P<0.05). The area under ROC for the patients with fibrosis stage ≥S1, ≥S2, ≥S3 and S4 was 0.833, 0.871, 0.906 and 0.919, respectively. Conclusion FibroScan could be used as a noninvasive technology to evaluate the hepatic fibrosis stage in patients with alcoholic liver disease.

Key words: Alcoholic liver disease, FibroScan, Hepatic fibrosis

徐微. FibroScan评估酒精性肝病肝纤维化程度的诊断价值[J]. 肝脏, 2016, 21(9): 719-721.

XU Wei. The clinical value of FibroScan for evaluating the hepatic fibrosis stage in patients with alcoholic liver disease[J]. Chinese Hepatolgy, 2016, 21(9): 719-721.

[1]	周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究[J]. 肝脏, 2020, 25(5): 521-524.
[2]	宁惠明, 徐燕华. 非酒精性脂肪性肝病患者血清视黄醛结合蛋白4的变化及临床意义[J]. 肝脏, 2020, 25(4): 429-432.
[3]	张娟, 徐少勇, 赵晓宏, 黄雪, 张根生, 周庆元. 非酒精性脂肪性肝病患者肠道微生态差异性及其与糖脂代谢相关指标的关系[J]. 肝脏, 2020, 25(4): 432-435.
[4]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎外周血浆样树突状细胞与免疫应答的关系及干预分析[J]. 肝脏, 2020, 25(1): 34-35.
[5]	李松, 张娟. 替诺福韦酯对乙型肝炎肝硬化患者肝纤维化状态与Th1/Th2型细胞因子的影响研究[J]. 肝脏, 2020, 25(1): 54-55.
[6]	李平生, 崔恒官. PNPLA3基因多态性与酒精性肝病发生的关系[J]. 肝脏, 2020, 25(1): 83-85.
[7]	刘薇, 袁海霞, 时强. 抗病毒治疗慢性乙型肝炎肝硬化后肝纤维化逆转情况观察[J]. 肝脏, 2019, 24(9): 1055-1057.
[8]	周晓颖, 王琳, 崔祖丽. Fibroscan对乙型肝炎并发酒精性肝病患者肝脏纤维化的诊断效果[J]. 肝脏, 2019, 24(9): 1058-1060.
[9]	刘琴, 时建国. MANF蛋白对乙型肝炎患者肝脏纤维化程度的诊断效果分析[J]. 肝脏, 2019, 24(9): 1063-1065.
[10]	陆伟, 刘丹萍, 张占卿, 王雁冰, 丁荣蓉, 周新兰, 黄丹, 李秀芬, 杨可芷. APRI、GPR和FIB-4预测抗病毒诱导的乙型肝炎肝硬化肝脏病理学回归的性能评价[J]. 肝脏, 2019, 24(8): 875-882.
[11]	武永萍, 魏占芳, 石栓柱, 马莉莎, 朱悦. 瞬时弹性超声成像在评价乙型肝炎肝纤维化严重程度中的价值[J]. 肝脏, 2019, 24(8): 905-907.
[12]	高峻, 郭旭升, 韩利杰. 血清ASMase水平对非酒精性脂肪性肝病患者肝纤维化程度的预测价值[J]. 肝脏, 2019, 24(8): 926-928.
[13]	王乐, 钱毅骏. 活性维生素D3联合IFN-α对肝纤维化小鼠肝纤维化程度、IL-6、TNF-α、TGF-β及Smad3表达的影响[J]. 肝脏, 2019, 24(8): 944-947.
[14]	孙涛, 杜凤梅, 戴立娟. 恩替卡韦治疗对慢性乙型肝炎患者血糖和血脂的影响[J]. 肝脏, 2019, 24(6): 680-683.
[15]	林雪茹, 王福祥. 丹酚酸B抑制肝纤维化-肝癌小鼠进展的信号通路研究[J]. 肝脏, 2019, 24(6): 683-686.